where we can bring these products, we now have the global presence to bring it to every market where there is need and where it makes economic sense. If you look at the diversity of our
portfolio, we cross therapeutic areas, 1,400 molecules and across different categories; were in the generics, were in compact generics, were in biosimilars, were in brands and were in OTC. And we believe that diversity
actually brings strength.
It brings strength because we can customize our portfolio to the needs of individual markets, it also brings strength because
we think it makes us a more credible partner to improve outcomes, to work with health care providers, to work with payers, to work with health care systems, precisely because were not focused on a few molecules, but in each therapeutic area,
we got a whole suite of products that we can credibly offer to this partnership.
And very importantly, and this speaks to our future growth, we get a lot
of questions about where the next wave of growth is going to come from. We believe that we can be a partner of choice for midsized products. Not the $1 billion blockbuster that everybody else is competing over, but the many innovators, many of
them at J.P. Morgan here, that dont have access to such a global health care gateway. What we can bring to them is a broad commercial reach across therapeutic areas across channels, whether its hospital, retail, et cetera, tendering, a
global supply network of over 50 sites. Theres not only high-quality, but it gives you also local proximity.
Expansive technical expertise, whether
its regulatory, pharmacovigilance, medical, development, pharmaceutical science, we can provide that as well. And last but not least, a cost-efficient operating platform. With that, we think we could get value, well be the partner of
choice and create better value for all the stakeholders. So with that, to tell you a little bit more about that gateway, Im going to hand it over to Rajiv Malik.
Rajiv Malik: Thank you, Michael, and good morning, everybody. So by this time in the presentation, I think you all must be having developing an appreciation
of why we believe that Viatris is going to have a unique profile. And Im personally very excited to bring this vision to life with Michael. So let me start with giving you an appreciation of the unparalleled global reach, 165-plus markets.
We always had the markets, but I think Upjohn or this transaction has brought us critical mass and
scale in markets like China, Latin America as well as the Middle East. We have 13,000 sales force across the world, 1,100 marketing professionals helping us push through 1,400-plus molecules, 13,000 SKUs
across multiple channels and across multiple therapeutic areas. How are we going to deliver it? We are going to deliver this through our high-quality, cost-efficient, vertically integrated global supply chain network of about 50 sites, which is
capable of producing right from the oral solids, injectables, transformers, thin films, you name a dosage form, and this platform can deliver that.
Were going to have, as I mentioned over here, this platform is capable of producing 80 billion doses. What Upjohn brought us is much more from the
proximity to the key markets, and also presence in certain markets, where local manufacturing is a